| 2026-08-10 | Press release | Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference |
| 2026-08-04 | Press release | Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference |
| 2026-08-04 | Press release | Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman |
| 2026-08-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-08-03 | Transcript | Earnings call transcript |
| 2026-07-30 | Press release | NEWS RELEASE Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential írst-in-class EGFR-and MET-targeted subcutaneous treatment for advanced head and neck cancer |
| 2026-07-29 | Press release | Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset |
| 2026-07-29 | Press release | Johnson & Johnson Completes Acquisition of Fireîy Bio, Inc. to Advance Next-Generation Oncology Innovation |
| 2026-07-29 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-28 | 8-K | Form 8-K, Item 7.01 |
| 2026-07-27 | Press release | Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation |
| 2026-07-23 | Press release | NEWS RELEASE TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma |
| 2026-07-23 | 10-Q | Form 10-Q for the quarter ended Jun 28 |
| 2026-07-22 | Press release | Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System |
| 2026-07-16 | Press release | Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award |
| 2026-07-15 | Press release | Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026 |
| 2026-07-15 | Deck | 2nd Quarter 2026 Earnings Call |
| 2026-07-15 | Press release | For immediate release Johnson & Johnson reports Q2 2026 results, raises 2026 outlook |
| 2026-07-15 | Press release | Johnson & Johnson reports Q2 2026 results, raises 2026 outlook |
| 2026-07-15 | Deck | Earnings presentation · Q2 2026 · Jul 2026 |
| 2026-07-15 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-15 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-14 | Supplement | Johnson & Johnson and Subsidiaries Supplementary Sales Data · Q2 2026 |
| 2026-07-08 | Press release | Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform |
| 2026-06-29 | Press release | DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer |
| 2026-06-26 | Press release | Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis |
| 2026-06-26 | Press release | Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress |
| 2026-06-15 | Press release | Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida |
| 2026-06-13 | Press release | New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-íhj) data demonstrate the strength of a bispeciíc combination in earlier-line relapsed or refractory multiple myeloma |
| 2026-06-13 | Press release | New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength |
| 2026-06-11 | Press release | Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients |
| 2026-06-11 | Press release | NEWS RELEASE IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of eìect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies |
| 2026-06-11 | Press release | IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study |
| 2026-06-08 | Press release | Johnson & Johnson to Acquire Fireîy Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform |
| 2026-06-03 | Press release | Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease |
| 2026-06-03 | Press release | Johnson & Johnson late-breaking results show nipocalimab signiícantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study |
| 2026-06-03 | Press release | Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) di |
| 2026-05-31 | Press release | NEWS RELEASE RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited |
| 2026-05-31 | Press release | Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery signiícantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm |
| 2026-05-29 | Press release | NEWS RELEASE RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical beneít as a írst-line treatment for atypical EGFR-mutated non-small cell lung cancer |